The hypothalamic melanocortin-4 receptor (MC4R), a seven transmembrane G-protein coupled receptor, plays an important role in the regulation of body weight. The synthetic melanocortin analogue SHU9119 has been widely used to characterize the physiological role of MC4R in feeding behavior and energy homeostasis. Previous studies indicated that SHU9119 is an agonist at the melanocortin-1 receptor (MC1R) but an antagonist at the melanocortin-4 receptor (MC4R); however, the molecular basis of the interaction between hMC4R and SHU9119 has not been clearly defined. To gain insight into the molecular determinants of hMC4R in the selectivity of SHU9119 chimera, and mutants hMC1R and hMC4R were expressed in cell lines and pharmacologically analyzed. A region of receptor containing the third transmembrane (TM3) of hMC4R was found to be required for selective SHU9119 antagonism.
Introduction
The melanocortin-4 receptor (MC4R) is a seven-transmembrane G -protein coupled receptor, principally expressed in the hypothalamic nucleus. This receptor plays an important role in the regulation of body weight in rodents and humans (1) (2) (3) . When stimulated by its putative physiologic agonist, α-melanocyte-stimulating hormone (α-MSH) inhibits feeding in mice through MC4R. Furthermore, mice with MC4R deletion develop hyperphagia, hyperinsulinism and obesity (4) . Recently, mutations in the MC4R have been reported as the most common causes of monogenic human obesity (5-7). MC4R mutations may play a particularly important role in early-onset childhood obesity, resulting in more severe obesity related complications such as hypertension and diabetes when compared to late onset obesity found in adults (8, 9) . In light of these findings, the molecular basis of the role that MC4R plays in obesity has been the subject of intense investigation.
Many new, potent, and enzyme-resistant analogs of melanocortin peptides have been developed based on the extensive studies of the melanocortin peptide, α-MSH (10) (11) (12) . These include NDP-MSH [Nle4,Dphe7]-α-MSH and Melanotan II (MTII, the lactam Ac-Nle4 cycle[Asp-His6-Dphe7-Arg8-Trp9-Lys10]-amide), which have been identified as potent, non-selective agonists at human melanocortin 1,3,4 and 5 receptors. In addition, the analog, SHU9119, a synthetic peptide with a b -(2-naphthyl)-Dalanine (D-Nal) substituted in position 7 of MTII, has been found to be a potent, but non-selective, antagonist for the MC3 and MC4 receptors (13, 14) . Intracerebroventricular (ICV) administration of MTII has been found to induce weight loss, while SHU9119 has been found to increase animal food intake and body weight (15, 16) . Because of potentially important therapeutic implications in the treatment of obesity and perhaps anorexia syndromes, determination of the molecular basis for ligand-receptor interaction between hMC4R and melanocortin peptides is valuable (17, 18) . Structure-function studies of NDP-MSH have demonstrated that Dphe-Arg-Trp of NDP-MSH is the minimal peptide required for hMC4R binding and activation. Furthermore, the conserved residues in TM3 and TM6 of melanocortin receptors have been found to be involved in NDP-MSH and MTII binding (18) . Mutation of the conserved MC4R TM3 residues aspartic acid 122 and 126 and TM6 residues Phenylalanine 261 and Histidine 264 significantly decrease the binding affinity and potency of NDP-MSH and MTII (18) . Little information is available, however, regarding the molecular basis of hMC4R interaction with the antagonist SHU9119. Whether SHU9119 utilizes the same hMC4R-binding site as NDP-MSH and MTII is unknown. In order to gain insight into the molecular determinants of hMC4R responsible for SHU9119 selectivity and particularly to define hMC4R residues essential for SHU9119 antagonist selectivity, we have taken a broad approach to investigating the role of the transmembrane (TM) amino acid residues of MC4R in discriminating between MTII and SHU9119 receptor activation. Chimera and mutants of MC4R were constructed and studied.
We hope this approach will provide valuable insight into the molecular basis of ligand-receptor interaction between hMC4R as well as SHU9119 and provide new information for rational drug design of selective MC4R agonists and antagonists.
Binding Assays. After removal of media cells were incubated with various non-radioligands in 0.5 ml MEM (Life Technologies) containing 0.2% BSA and radioligand. Binding experiments were performed using conditions previously described (19) subtracting nonspecifically bound radioactivity from total bound radioactivity.
cAMP Assay. cAMP generation was measured using a competitive binding assay kit (TRK 432, Amersham, Arlington Heights, IL). Briefly, HEK cell lines stably expressing the human melanocortin receptors, previously described, were used in these assays (19) . Cell culture media was removed, and cells were incubated with 0.5 ml Earle's Balanced Salt Solution (EBSS), containing melanocortin agonist NDP-MSH, MTII or antagonist SHU9119 (10 -10 -10 -6 M), for 30 min at 37°C in the presence of 10 -3 M isobutylmethylxanthine. The reaction was stopped by adding ice-cold 100% ethanol (500 µl/well). The cells in each well were scraped, transferred to a 1.5 ml tube, and centrifuged for 10 min at 1900 x g , and the supernatant was evaporated in a 55°C water bath with pre-purified nitrogen gas. cAMP content was measured according to instructions accompanying the assay kit. Each experiment was performed a minimum of three times with duplicate wells. The mean value of the dose-response data were fit to a sigmoid curve with a variable slope factor using non-linear squares regression analysis ( Graphpad Prism, (Graphpad Software, San Diego, CA). All statistical analyses represent the mean of the data ± standard error.
Results

Characterization of hMC4R/hMC1R chimera with 125 I NDP-MSH binding
To investigate the molecular determinant of hMC4R responsible for SHU9119 binding and specific activity, a domain-swapping strategy was used to localize regions of the receptor responsible for ligand receptor selectivity. Cassette substitutions of the third, fourth, fifth, and sixth transmembrane regions of the hMC4R with homologous regions of the hMC1R were constructed. The first, second, and seventh trasmembranes were not chosen for investigation because computer modeling of ligand receptor interaction and our previous data suggested that they were not important in NDP-MSH binding (18, 19) .
The binding affinities of NDP-MSH, MTII and SHU9119 at wild type hMC4 and hMC1 receptors were first examined. As shown in Figure 3 
Characterization of hMC4R/hMC1R chimera with cAMP assays
To examine the ability of NDP-MSH, MTII and SHU9119 to activate hMC4/hMC1 chimeric receptors, cAMP production was determined. For wild-type hMC1R and hMC4R, both NDP-MSH and MTII dose-dependently increased cAMP generation as expected. SHU9119 dose-dependently induced cAMP generation at hMC1R but had no effect however on cAMP production at hMC4R
( Figure 3 , panel B.D). For the hMC4/hMC1 chimeric receptors, both NDP-MSH and MTII also increased cAMP generation in a dose-dependent manner ( Figure 4 ). SHU9119 had no effect on cAMP levels in cells expressing the chimeric hMC4R/4TMhMC1R, hMC4R/5TMhMC1R, and hMC4R/6TMhMC1R. However, when TM3 of hMC4R was replaced with the corresponding region of hMC1R, SHU9119 switched from antagonist to agonist, resulting in increased cAMP production ( Figure   4 ). Their EC 50 values are shown in Table 1 .2. These results identify the TM3 region of both hMC1R
and hMC4R as critical molecular determinant of SHU9119 activity.
Identification of amino acid residues in TM3 of hMC4R responsible for SHU9119 selectivity
Because exchange of TM3 of hMC4R with the corresponding region of hMC1R altered SHU9119 specific activity, it was important to determine which amino acid residues of TM3 of hMC4R were responsible for SHU9119 specific activity. The sequence of amino acids of hMC4R TM3 is depicted in Figure 5 . A sequence alignment of hMC1R and hMC4R revealed that the TM3 domain is highly conserved; however, there are nine amino acids differences (see figure 2 ). Based on the sequence alignment, seven candidate amino acids of potential importance for antagonist SHU9119 activity were selected for mutation analysis. L141 and S142 were excluded from mutation analysis because these amino acids are located in the deep intracellular side. To define which amino acid is involved in D-Nal 7 of SHU9119 antagonism, the reciprocal exchange of amino acids of TM3 between hMC4R and hMC1R was used. These seven TM3 hMC4R residues were individually replaced by the homogeneous residues of hMC1R, expressed in HEK cells and evaluated. As shown in Table 2 Effect of amino acid substitution of hMC1R on ligand SHU9119 binding and activation.
Since replacement of L133 of the hMC4R with the homologous residue M of the hMC1R switched SHU9119 from antagonist to agonist, we hypothesized that the residues of other melanocortin receptor subtypes corresponding to 133 of hMC4R might also be important for selecting agonist or antagonist. In order to test this hypothesis we made cassette substitutions of the hMC1R residue M128 with the homologous residue of the hMC4R L133. We expected that if the M128 residue was important for ligand selectivity, the MC1R mutant (M128L), unlike wild-type MC1R, would be able to convert agonist SHU9119 into antagonist or at least reduce MTII and SHU9119 potency. Consistent with our assumption, our results demonstrated that the hMC1R mutant with substitution of L of hMC4R dramatically reduced MTII and SHU9119 binding affinity and potency comparable to that of the "wildtype" hMC1R,though there was no effect on NDP-MSH binding affinity and potency ( Figure 7 ). The substitution of hMC1R did not switch SHU9119 from agonist to antagonist however.
Discussion
Hypothalamic MC4R plays an important role in the regulation of animal food intake. The melanocortin receptor agonist, MTII and antagonist SHU9119 have been widely used in the study of MC receptor functions (20) (21) (22) . The identification of the essential amino acid residues of human MC4R responsible for SHU9119 antagonism should be important for the understanding of the signaling events that regulate the melanocortin system under physiologic circumstances. In addition, a molecular understanding of SHU9119 activity at hMC4R may have important implication in the design of drug that may regulate feeding behavior in conditions such as obesity or anorexia.
The natural melanocortins (α-MSH, β-MSH, γ-MSH and ACTH) and synthetic melanocortins (NDP-MSH, MTII, SHU9119) have distinct affinity profiles for each of the five MC receptor subtypes.
The natural melanocortins are all agonists for hMCRs with the exception of MC2R, for which only ACTH and activity led to the discovery of SHU9119, in which a bulky hydrophobic amino acid in 7 position of MTII converts the peptide from an agonist to an antagonist at the MC3R and MC4R (13) . However, the molecular basis responsible for this antagonism is unclear. In the present study, we use a domainswapping strategy to localize regions of the hMC4R responsible for SHU9119 antagonism. hMC4R and hMC1R were chosen to construct chimera since the hMC4R and hMC1R belong to the same receptor family yet SHU 9119 is an agonist at MC1R and an antagonist at MC4R (25, 26) . Our chimeric receptor studies demonstrated that the third transmembrane domain (TM3) of the hMC4R is responsible for To determine whether residue TM3 leucine133 of hMC4R is specific for SHU9119 activity or whether it is a critical residue common for other melanocortin receptors, we mutated homologous residue in TM3 of hMC1R, methione128 to leucine128. Our results indicate that the mutation of M128L does not affect NDP-MSH binding affinity but does dramatically decreased MTII and SHU9119 binding affinity. This finding strongly suggested that NDP-MSH had different binding sites from MTII and SHU9119 at hMC1R and that M128 is crucial for MTII and SHU9119 binding but is not important for NDP-MSH binding. One possible explanation for this finding might be that NDP-MSH is a linear peptide and can compensate the binding site while MTII and SHU9119 are cyclic peptides. Cyclic peptides structures are more restricted than that of NDP-MSH and therefore the fact that substitution of M128 in hMC1R, the amino acid corresponding to L133 of hMC4R, did not switch SHU9119 from agonist to antagonist indicates that residue 133 in hMC4R is unique for SHU9119 selectivity and it is not the common nature for all melanocortin receptor subtypes. Our results indicated that more than one amino acid residue are required for SHU9119 activation at the hMC1R. Residue M128 at the hMC1R is involved in both MTII and SHU9119 binding, but the L 133 residue at the hMC4R is the only specific residue that differentiates DPhe and DNal activity.
It has been reported that two amino acids Phenylalanine in TM6 of the mouse MC4R are involved in SHU9119 antagonism (27) . However, our data demonstrate that replacement of TM6 of human MC4R
with TM6 of human MC1R has no effect on SHU9119 activity. Furthermore, sequence analysis of both hMC1R and hMC4R TM6 indicates that both receptors have two phenylalanine residues at the same position. If phenylalanine in TM6 of hMC4R were crucial for SHU9119 specific activity it would be unlikely that SHU9119 would have a different action at hMC1R compared to hMC4R. One explanation for this discrepancy might be that human MC4R has different binding sites for SHU9119 compared with that of mouse MC4R.
In conclusion, these results provide insight into the molecular features of hMC4R responsible for SHU9119 antagonist specific activity. This study shows that mutation of hMC4R L133 to methione switches SHU9119 from antagonist to agonist while not changing NDP-MSH, MTII or SHU9119 binding affinity and M128 in hMC1R is important for MTII and SHU9119 binding and activation. This report also suggests that melanocortin peptides utilize conserved residues for receptor binding while generation at the hMC1R but has no effect at hMC4R. The basal cAMP level is 0.42 ± 0.01 pM for wild-type hMC1R, 0.63 ± 0.10 pM for wildtype hMC4R, 0.44 ± 0.12 pM for hMC4R/3TMhMC1R, 0.48 ± 0.09 pM for hMC4R/4TMhMC1R, 1.2 ± 0.3 pM for hMC4R/5TMhMC1R, 0.39 ± 0.14 pM for hMC4R/6TMhMC1R. The data shown are mean ± SE of at least three independent experiments. 
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